Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bet1 Golgi vesicular membrane trafficking protein (BET1) is a SNARE family membrane protein required for vesicular transport from the endoplasmic reticulum (ER) to the Golgi complex[2][3][5]. BET1 contributes to docking and fusion of ER-derived vesicles with the cis-Golgi membrane and forms part of the multi-protein SNARE complex essential for this process. Mutations in the BET1 gene disrupt intracellular trafficking, and have been shown to cause severe congenital muscular dystrophy and epilepsy, highlighting its relevance in normal secretory pathway functioning and protein glycosylation. BET1 interacts with proteins including Syntaxin-5, SEC22b, GOSR2, and also with ERGIC-53, the latter of which is important for correct protein localization. BET1 is not a current therapeutic target or drug receptor, but defects in its function can cause human disease due to impaired vesicular trafficking[1][2][3][5].
Not applicable; there are currently no drugs known to directly target this protein
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bet1 Golgi vesicular membrane trafficking protein (BET1).